These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20075048)

  • 21. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated.
    Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
    Vaccine; 2007 Jun; 25(23):4631-40. PubMed ID: 17478015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.
    Ochoa-Gondar O; Vila-Corcoles A; Ansa X; Rodriguez-Blanco T; Salsench E; de Diego C; Raga X; Gomez F; Valdivieso E; Fuentes C; Palacios L;
    Vaccine; 2008 Apr; 26(16):1955-62. PubMed ID: 18343541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
    Fedson DS
    Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.
    Domínguez A; Castilla J; Godoy P; Delgado-Rodríguez M; Saez M; Soldevila N; Astray J; Mayoral JM; Martín V; Quintana JM; González-Candelas F; Galán JC; Tamames S; Castro A; Baricot M; Garín O; Pumarola T;
    Hum Vaccin Immunother; 2013 Apr; 9(4):865-73. PubMed ID: 23563516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study.
    Hechter RC; Chao C; Jacobsen SJ; Slezak JM; Quinn VP; Van Den Eeden SK; Tseng HF
    Vaccine; 2012 Aug; 30(38):5625-30. PubMed ID: 22789510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
    Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
    Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease.
    Imaz A; Falcó V; Peñaranda M; Jordano Q; Martínez X; Nadal C; Curran A; Planes AM; Dalmau D; Ribera E; Riera M; Ruiz de Gopegui E; Pahissa A
    HIV Med; 2009 Jul; 10(6):356-63. PubMed ID: 19490180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.
    Puig-Barberà J; Diez-Domingo J; Pérez Hoyos S; Belenguer Varea A; González Vidal D
    Vaccine; 2004 Dec; 23(3):283-9. PubMed ID: 15530669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
    Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
    Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
    Musher DM; Rueda-Jaimes AM; Graviss EA; Rodriguez-Barradas MC
    Clin Infect Dis; 2006 Oct; 43(8):1004-8. PubMed ID: 16983612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007).
    Gil-Prieto R; García-García L; Alvaro-Meca A; Méndez C; García A; de Miguel AG
    Vaccine; 2011 Jan; 29(3):412-6. PubMed ID: 21111780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.
    Alfageme I; Vazquez R; Reyes N; Muñoz J; Fernández A; Hernandez M; Merino M; Perez J; Lima J
    Thorax; 2006 Mar; 61(3):189-95. PubMed ID: 16227328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of prior pneumococcal and influenza vaccination on outcomes of older adults with community-acquired pneumonia.
    Manzur A; Izquierdo C; Ruiz L; Sousa D; Bayas JM; Celorrio JM; Varona W; Nebot M; Salleras L; Domínguez A; Carratalà J;
    J Am Geriatr Soc; 2011 Sep; 59(9):1711-6. PubMed ID: 21806565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥60 years-a population-based retrospective cohort study.
    Kolditz M; Schmitt J; Pletz MW; Tesch F
    Clin Microbiol Infect; 2018 May; 24(5):500-504. PubMed ID: 28830805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.
    Pírez MC; Algorta G; Cedrés A; Sobrero H; Varela A; Giachetto G; Montano A
    Pediatr Infect Dis J; 2011 Aug; 30(8):669-74. PubMed ID: 21407145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
    Ortqvist A; Henckaerts I; Hedlund J; Poolman J
    Vaccine; 2007 Mar; 25(13):2445-50. PubMed ID: 17052816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.
    Chiou WY; Hung SK; Lai CL; Lin HY; Su YC; Chen YC; Shen BJ; Chen LC; Tsai SJ; Lee MS; Li CY
    Medicine (Baltimore); 2015 Jul; 94(26):e1022. PubMed ID: 26131806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of pneumococcal conjugate vaccine against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African children: a case-control study.
    Madhi SA; Groome MJ; Zar HJ; Kapongo CN; Mulligan C; Nzenze S; Moore DP; Zell ER; Whitney CG; Verani JR
    Thorax; 2015 Dec; 70(12):1149-55. PubMed ID: 26092924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.
    Vila-Corcoles A; Hospital-Guardiola I; Ochoa-Gondar O; de Diego C; Salsench E; Raga X; Fuentes-Bellido CM
    BMC Public Health; 2010 Jan; 10():25. PubMed ID: 20085658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.